CNTNAP2 and epilepsy: Although patients with anti-LGI-1 and CASPR2 antibodies are characterized by clinical heterogeneity, they also demonstrate considerable overlap in clinical symptomatology; anti-LGI1 antibodies are most commonly associated with epilepsy and limbic encephalitis, while anti-CASPR2 antibodies are associated with neuromyotonia, Morvan syndrome, and neuropathic pain.